Mr. Christopher Hopton reports

SIRONA BIOCHEM CORPORATE UPDATE JANUARY 2024

Sirona Biochem Corp. has provided the following update.

Dear shareholders,

We are pleased to provide an update on our recent milestones and strategic decisions shaping Sirona Biochem's path forward.

Trademark of TFC-1326 as GlycoProteMim

We recently trademarked TFC-1326 as GlycoProteMim. This branding decision aims to distinguish our anti-aging active ingredient in a competitive market by giving it an easily recognizable identity while also enhancing its marketability and positioning it as a sought-after solution in the beauty industry. With a diverse array of options for consumers to address visible signs of aging, our brand aims to be one that people can be educated about, understanding its benefits and easily identifying it in the marketplace.

Establishment of Sirona Laboratories

We are excited to introduce Sirona Laboratories, a newly established entity dedicated to commercializing GlycoProteMim. This decision is rooted in our commitment to expedite the commercialization process and provide a streamlined avenue for market penetration.

Sirona Biochem will maintain majority ownership in the subsidiary. This will ensure a more streamlined and efficient commercialization process by eliminating the common delays associated with external partnerships. We are poised to bring this innovative skin care solution to market in the shortest time possible.

Ultimately, the creation of Sirona Laboratories stands as a strategic move that directly benefits our stakeholders. It not only safeguards shareholder interests but also positions GlycoProteMim as a valuable asset within a separate entity, presenting potential avenues for capitalization on its technology while preserving the integrity of Sirona Biochem.

In the aesthetic space, brand acquisitions at high valuations are common, and novel technology optimally capitalized when part of an established brand. Beauty brand mergers and acquisitions are predicted to be a growing market trend.

Preparation for commercialization of GlycoProteMim

Final process development for the manufacturing of GlycoProteMim by Wuxi AppTec has been completed, and it is ready to produce multikilogram orders upon request. Work is well under way on multiple other fronts necessary to produce a high-quality consumer product. Further updates will be made near term regarding the team of experts we are assembling for this task.

It is our intention to launch our first consumer product containing GlycoProteMim in both Europe and North America through our subsidiary Sirona Laboratories, then expanding to other markets globally. With the necessary financing, we have set out a plan to launch our first product early in the first quarter of 2025. The fundamental science is clinically proved, and safety established, so the work needed is mainly to satisfy technical requirements of a new product and re-establish its effectiveness necessary to allow appropriate product claims.

TFC-1067 -- global licensing agreement with Allergan Aesthetics

Allergan continues to work toward integration of TFC-1067 into its pipeline. Once permissible, we will update our shareholders accordingly. Sirona Biochem's management remains in regular communication with Allergan Anesthetic's team.

Anti-viral library, diabetes, and other new research and development projects

TFChem's scientists at Sirona Biochem are actively involved in progressing the anti-viral and SGLT 2 diabetic project. Despite this continuing effort, these projects are not currently the top priority. The primary focus of the team is directed toward pioneering new developments within the aesthetic space. It is worth noting that certain aspects of their work are kept confidential until they reach a stage where intellectual property can be securely established.

Making Sirona Laboratories a market success

To materialize the success of GlycoProteMim, we will be securing strategic financing from private equity funds and investors. This infusion of substantial upfront capital is earmarked for crucial aspects such as inventory, retail infrastructure and impactful marketing efforts, which will all contribute to a robust and successful product launch.

Envisioning beyond a single product, Sirona Biochem sees a future of diversified offerings with multiple products utilizing GlycoProteMim. Preserving shareholder value is a core principle in our strategy. By avoiding significant dilution and control issues, we ensure that our shareholders enjoy a substantial portion of the revenue stream generated by GlycoProteMim.

Other profitable markets

Beyond GlycoProteMim, we can continue to advance projects in areas such as cellulite, wound care and keloid treatments, underscoring our commitment to comprehensive skin care solutions. Sirona Laboratories is poised to bring to market not only GlycoProteMim but also new cosmeceuticals developed by TFChem. This collaboration enhances our ability to introduce a diverse and wide range of innovative skin care solutions.

By pursuing a quicker route to profitability, we reduce reliance on recurrent financing, ensuring stability and a sustainable growth trajectory for Sirona Biochem and its subsidiaries. Sirona Biochem's stable financial source paves the way for bringing numerous backlogged ideas from our scientific team into commercial reality. This pro-active approach to innovation ensures that our pipeline remains dynamic and responsive to emerging skin care needs.

About Sirona Biochem Corp.

Sirona Biochem is a cosmetic ingredient and drug discovery company with proprietary platform technology. Sirona Biochem specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona Biochem's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and continuing royalty payments. Sirona Biochem's laboratory, TFChem, is located an hour north of Paris, France, and is the recipient of multiple French national scientific awards and European Union and French government grants.

We seek Safe Harbor.